EDGEWISE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.33 USD | -8.35% |
|
-6.10% | +67.55% |
| May. 10 | Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating | MT |
| May. 09 | Edgewise Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 1.71B |
|---|---|---|---|---|---|
| Net income 2024 * | -143M | Net income 2025 * | -174M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 152M | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-10.4
x | P/E ratio 2025 * |
-9.57
x | Employees | 92 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.54% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -8.35% | ||
| 1 week | -6.10% | ||
| Current month | +2.17% | ||
| 1 month | +15.07% | ||
| 3 months | -5.86% | ||
| 6 months | +232.67% | ||
| Current year | +67.55% |
1 week
17.96
21.60
1 month
14.9021.60
Current year
9.0021.60
1 year
5.1221.60
3 years
5.1229.98
5 years
5.1240.49
10 years
5.1240.49
| Managers | Title | Age | Since |
|---|---|---|---|
Alan Russell
FOU | Founder | 54 | 16-12-31 |
Kevin Koch
CEO | Chief Executive Officer | 63 | 16-12-31 |
R. Carruthers
DFI | Director of Finance/CFO | 66 | 20-10-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jon Root
BRD | Director/Board Member | 64 | 19-07-31 |
Kevin Koch
CEO | Chief Executive Officer | 63 | 16-12-31 |
Peter Thompson
FOU | Founder | 64 | 16-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 0 M€ | 0.00% | - | |
| 0.03% | 0 M€ | 0.00% | - | |
| 0.00% | 0 M€ | +9.18% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 18.33 | -8.35% | 1,139,404 |
| 24-05-09 | 20 | -4.26% | 1,026,485 |
| 24-05-08 | 20.89 | -1.60% | 686,921 |
| 24-05-07 | 21.23 | +4.38% | 777,039 |
| 24-05-06 | 20.34 | +4.20% | 587,400 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotes
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing novel therapeutics for muscular dystrophies and serious cardiac conditions. It has built its muscle-focused drug discovery platform. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. Its lead product candidate, EDG-5506, is an orally administered allosteric, selective, fast myofiber (type II) myosin small molecule inhibitor designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy and Becker muscular dystrophy. Its product candidate, EDG-7500, for the treatment of hypertrophic cardiomyopathy addition to exploring the potential of its mechanism in the treatment of disorders of diastolic dysfunction.
Calendar
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
18.33
USD
Average target price
31.17
USD
Spread / Average Target
+70.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +67.55% | 1.71B | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- EWTX Stock
